ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
SMYD3 Promotes Immune Evasion in Clear Cell Renal Cell Carcinoma via SREBP1-Mediated Transactivation of CD47.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Core Fucosylation Represses SMURF1-Dependent Degradation of CD47 to Promote Tumor Immune Evasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- NUDT7 Modulates the UBA52-SREBF1 Signaling Axis to Promote PRRSV Replication via Lipid Synthesis.International journal of biological sciences · 2026Article
- SMYD3 Promotes Immune Evasion in Clear Cell Renal Cell Carcinoma via SREBP1-Mediated Transactivation of CD47.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Cancer cell-intrinsic features (e.g., genetic aberrations and dysregulation of signaling pathways) play pivotal roles in orchestrating the composition and functional state of the immune landscape, which in turn impact tumor progression and response to immunotherapy. Here, it is discovered that dysregulation of cancer cell-intrinsic SET and MYND domain-containing protein 3 (SMYD3) leads to the orchestration of an immunosuppressive microenvironment and the impairment of responses to PD-1 blockade by reprogramming the infiltration of immune cells in the tumor microenvironment of clear cell renal cell carcinoma (ccRCC). SMYD3 cooperates with Sp1 to transcriptionally promote sterol regulatory element-binding protein 1 (SREBP1) expression by modifying H3-K4 di-/trimethylation and consequently activating the transcription of CD47. CD47, a bridge between innate and adaptive immunity, acts as the downstream effector molecule of the SMYD3 signal to promote the infiltration of T helper 2 (Th2) cells, protecting renal cancer cells from immune attack. In summary, the critical role of the cancer cell-intrinsic SMYD3-SREBP1-CD47 axis is elucidated in regulating the immune microenvironment in ccRCC and provides a potential therapeutic strategy to manipulate the tumor immune milieu in favor of antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.